Hangzhou AllTest Biotech CO.,LTD 

      Your Reliable Rapid Test Partner!

About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home News

New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads

I'm Online Chat Now
China Hangzhou AllTest Biotech CO.,LTD certification
China Hangzhou AllTest Biotech CO.,LTD certification
I like the products and service provided by AllTest. They really take our interest into consideration.

—— Mr John Smith England

My oldest daughter actually has Lyme disease. She spent almost 1 year in a wheelchair because of Lyme. She is doing very well now. I used 2 of the samples. 1 to test my Lyme diagnosed daughter and 1 to test my daughter who does not have Lyme. Your tests worked well. My daughter with Lyme tested positive and the one who does not tested negative.

—— Ms Sheila

Whenever I have the requests,AllTest always give me the satisfied reply at the first time.

—— Mrs Julie Tschetter Belgium

As the old customer of AllTest since 2009, we should thank the great work have been done by AllTest to support us gain more market share and profit

—— Mr Robin Seifert Germany

Company News
New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads
Latest company news about New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads

WASHINGTON – A first-of-its-kind study published today in AACC’s Clinical Chemistry journal shows that a new protocol for coronavirus testing can increase clinical labs’ testing capacity without sacrificing accuracy. This protocol could play a vital role in helping labs keep up with coronavirus testing demands as the Delta variant fuels a new increase in COVID-19 cases around the world.


Due to the highly transmissible Delta coronavirus variant, global COVID-19 cases have gone up 12% in the past week, and the average of new daily cases in the U.S. in particular has surged by 145% over the past two weeks. Making matters worse, vaccination coverage continues to lag. Many resource-limited countries are still struggling to secure coronavirus vaccines, while in the U.S., vaccine hesitancy is hindering efforts to achieve herd immunity. More than half of the U.S. population is unvaccinated and highly likely to remain that way, according to a recent poll published by Axios-Ipsos. All of this means that PCR coronavirus tests—the gold-standard for diagnosing COVID-19—will continue to play a central role in managing the pandemic for the foreseeable future. It also means that, with the pandemic in this new growth phase, the supply shortages that stymied testing for the first year of the pandemic must be prevented from reoccurring.


latest company news about New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads  0


To support this goal, a team of researchers led by Lea Starita, PhD, and Christina Lockwood, PhD, of the University of Washington has developed a new, streamlined protocol for PCR coronavirus testing called SwabExpress. Typically, PCR coronavirus testing involves the extraction of viral genetic material from nasopharyngeal patient specimens transported in viral media. However, overreliance on this protocol throughout much of the pandemic contributed to a global shortage of extraction reagents, nasopharyngeal swabs, and viral media that hindered coronavirus testing even as recently as spring of 2021. SwabExpress, on the other hand, does not require viral media or extraction reagents, and also uses less invasive anterior nasal dry-swabs instead of nasopharyngeal swabs. All of this makes it ideal for averting future supply shortages and/or for use during periods of severe shortages.


In general, SwabExpress is much easier to perform than the standard PCR coronavirus testing protocol. After adopting SwabExpress, Starita and Lockwood’s laboratory approximately doubled its capacity for coronavirus testing. Importantly, unlike other extraction-free methods for nasal swabs that have been developed, SwabExpress is also highly accurate. The researchers demonstrated that it has a sensitivity of 100% and a specificity of 99.4% when compared side-by-side with a traditional PCR protocol.


“Massive scaling and deployment of SARS-CoV-2 testing is essential to curtailing the COVID-19 pandemic, and will likely be necessary well into the future,” said Starita and Lockwood. “The protocol evaluated here, including thousands of real-world, self-collected nasal swabs, would markedly simplify the workflow for RT-qPCR, the most widely deployed testing paradigm, by eliminating the need for viral transport media and RNA extraction. It may serve as a template for the simplification of PCR-based clinical laboratory tests, particularly in times of critical shortages during pandemics.”

Pub Time : 2021-09-07 09:07:48 >> News list
Contact Details
Hangzhou AllTest Biotech CO.,LTD

Contact Person: Mrs. Selina

Tel: +86 13989889852

Fax: 86-571-56267856

Send your inquiry directly to us